Last updated on November 2017

This study is a Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease.


Brief description of study

This study is a Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease.

Detailed Study Description

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a vein. The purpose of this research is: to find out if the study drug has a benefit on a person's cognitive (mental) status using a series of specialized cognitive tests, to learn if the drug is safe and well-tolerated in people with early Alzheimer's disease and to discover how much of the drug is in the blood at different times after injection.

Clinical Study Identifier: TX9171

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Sharp Mesa Vista Hospital Clinical ...

Sharp Mesa Vista Hospital Clinical Research Center
San Diego, CA USA
  Connect »